Akebia Therapeutics, Inc.
NASDAQ:AKBABiotechnology
+$0.01 today
- Market cap
- $113.54M
- Beta
- 0.25
- P/E (TTM)
- -13.3
- EPS (TTM)
- -$0.08
Volume 7.09M
Average 4.03M
AKBA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Akebia Therapeutics, Inc.NASDAQ: AKBA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $14.81M rose 51.8% year over year, behind the +78.1% change in trailing-twelve-month research & development. Sequentially, it fell 44.4% from the prior quarter. Over 3 fiscal years it compounded at -27.8% a year.
Context
- Research & development amounted to 26.4% of revenue in FY2025, up 2.9 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +51.8% toward the trailing-twelve-month pace of +78.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 62.36M USD
- Year-over-year change
- +65.6%
- 4-year CAGR
- -19.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 62.36M | +65.6% |
| FY2024 | 2024-12-31 | 37.65M | -40.3% |
| FY2023 | 2023-12-31 | 63.08M | -62.0% |
| FY2022 | 2022-12-31 | 165.99M | +12.3% |
| FY2021 | 2021-12-31 | 147.85M | — |
Research & Development vs competitors
How AKBA compares with its peers on the latest reported figures
- AKBA's LTM Mar 2026 research & development of $67.09M is the 5th highest of the 10 companies compared; the peer median is $56.29M.
- Its year-over-year change of +78.1% is the highest of 9, against a peer median of +35.1%.
- Research & development amounts to 28.9% of revenue for AKBA, versus a peer median of 104.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $219.98M | +42.7% | +34.6% | 249.3% | |
| LTM Mar 2026 | $186.6M | +29.5% | +0.6% | 336.0% | |
| LTM Mar 2026 | $176.31M | +40.8% | +24.2% | — | |
| LTM Mar 2026 | $96.67M | -53.8% | -0.2% | 166.8% | |
| LTM Mar 2026 | $67.09M | +78.1% | -27.8% | 28.9% | |
| LTM Mar 2026 | $56.29M | +22.7% | +23.1% | — | |
| LTM Dec 2025 | $48.42M | — | — | 41.8% | |
| LTM Mar 2026 | $37.44M | +64.5% | +11.3% | — | |
| LTM Mar 2026 | $36.54M | +41.7% | -17.9% | 12.2% | |
| LTM Mar 2026 | $13.88M | -59.9% | -13.7% | 11.3% | |
| Peer median (excluding AKBA) | $56.29M | +35.1% | +5.9% | 104.3% | |
Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 211.65M | 292.48M | 194.62M | 160.18M | 236.2M |
| Cost of Revenue | 81.49M | 22.5M | 74.15M | 63.18M | 39.46M |
| Gross Profit | 130.16M | 269.99M | 120.47M | 97M | 196.73M |
| Gross Margin | 61.5% | 92.3% | 61.9% | 60.6% | 83.3% |
| Research & Development | 147.85M | 165.99M | 63.08M | 37.65M | 62.36M |
| Selling, General & Admin | 174.14M | 138.6M | 100.23M | 106.55M | 107.48M |
| Operating Expenses | 394.66M | 350.77M | 166.73M | 147.48M | 173.24M |
| Depreciation & Amortization | 37.97M | 37.7M | 37.63M | 37.5M | 1.27M |
| EBITDA | (189.91M) | 3.06M | (8.27M) | (13.72M) | 21.73M |
| EBITDA Margin | -89.7% | 1.0% | -4.2% | -8.6% | 9.2% |
| Operating Income | (264.5M) | (80.78M) | (46.26M) | (50.47M) | 23.5M |
| Operating Margin | -125.0% | -27.6% | -23.8% | -31.5% | 9.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 19.94M | 15.69M | 6.03M | 18.19M | 24.18M |
| Other Income / Expenses | (17.52M) | (13.45M) | (5.67M) | (18.94M) | (27.22M) |
| Income Before Tax | (282.02M) | (94.23M) | (51.93M) | (69.41M) | (3.72M) |
| Pre-Tax Margin | -133.3% | -32.2% | -26.7% | -43.3% | -1.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.62M |
| Net Income | (282.02M) | (94.23M) | (51.93M) | (69.41M) | (5.35M) |
| Net Margin | -133.3% | -32.2% | -26.7% | -43.3% | -2.3% |
| EPS (Basic) | (1.48) | (0.58) | (0.28) | (0.33) | (0.02) |
| EPS (Diluted) | (1.48) | (0.58) | (0.28) | (0.33) | (0.02) |
| Weighted Avg Shares | 165.95M | 182.78M | 187.47M | 210.95M | 257.16M |
| Weighted Avg Shares (Diluted) | 165.95M | 182.78M | 187.47M | 210.95M | 257.16M |
Akebia Therapeutics, Inc.
NASDAQ:AKBA
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.